Results Confirm and Extend Response Results from Phase 3 FLASH Study
PRINCETON, N.J., May 4, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and. | May 4, 2023
/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
Phase 2/3-Ready Orphan Disease Program Complements Company s Existing Late-Stage Rare Disease Pipeline
PRINCETON, N.J., May 1, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage. | May 1, 2023
Soligenix, Inc. (NASDAQ:SNGX – Get Rating)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.33 and traded as high as $1.68. Soligenix shares last traded at $1.54, with a volume of 29,116 shares traded. Soligenix Trading Down 15.6 […]